Deflazacort induced stronger immunosuppression than expected.
Prednisone (PDN) impairs cognitive functioning and brain structures in humans and animals. Deflazacort (DFZ) is a synthetic glucocorticoid claimed to have lesser side effects than prednisone. The objective of this study was to assess whether chronic administration (90 days) of DFZ produces less neuronal degeneration and glial reactivity than PDN. Male Swiss-Wistar rats were studied. Controls received 0.1 ml distilled water orally. The PDN group received prednisone 5 mg per kg per day orally, and the DFZ group received deflazacort 6 mg per kg per day orally. This model had to be assembled in three different occasions due to excess mortality in the DFZ group. A fourth model was assembled using only the DFZ group and slides of water and PDN-exposed rats from a previous study were used as comparators. The index of degenerated neurons and the number and cytoplasmic transformation of astrocytes and microglia cells were evaluated in the prefrontal cortex, CA1, and CA3 hippocampus. The results show that the overall mortality was 49% in the DFZ group, 4.5% in the PDN group, and none of the controls died. Routine necropsy showed infection in multiple organs. The PDN group had two times higher neuronal degeneration in the prefrontal cortex, almost 11 times in CA1, and four times in CA3 hippocampus when compared with controls and DFZ group. Astrocytes reactivity was increased in the PDN- and DFZ-exposed rats compared with controls. The DFZ group showed an average of four times less microgial cells in the three studied regions when compared with controls and the PDN group. In conclusion, it seems that DFZ at the equivalent licensed dose produced a stronger immunosuppressive effect--systemic and in brain tissue--than PDN, but induced less neuronal damage. The immunosuppressant magnitude of DFZ should be further studied in clinical settings.
Gonzalez-Castañeda
Rocio E
RE
Neuroscience Division, Centro de Investigación Biomédica de Occidente del Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
Castellanos-Alvarado
Estela Adriana
EA
Flores-Marquez
Maria Rosa
MR
Gonzalez-Perez
Oscar
O
Luquin
Sonia
S
Garcia-Estrada
Joaquin
J
Ramos-Remus
Cesar
C
D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000473:pathology; D001424:Bacterial Infections; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D011241:Prednisone / Q000009:adverse effects; D017397:Prefrontal Cortex / Q000187:drug effects / Q000473:pathology; D011282:Pregnenediones / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011282:Pregnenediones; C021988:deflazacort; D011241:Prednisone